Study of L-DOPA Treatment for Depression with High Inflammation and Anhedonia in Adults Aged 25-55

What this Trial Is About

Researchers are studying new treatment options for adults aged 25 to 55 who have depression characterized by high inflammation and anhedonia, which is the inability to feel pleasure. This 8-week, double-blind, placebo-controlled trial explores the effects of an FDA-approved medication called Sinemet L-DOPA in this specific group of people. The study aims to better understand whether L-DOPA affects brain circuits related to motivation and reward in depression. Participants will be randomly assigned to receive either L-DOPA or a placebo. Those in the L-DOPA group will start with one tablet daily containing 150 mg levodopa and 37.5 mg carbidopa for 4 weeks. Responders continue this dose for another 4 weeks, while non-responders increase to three tablets daily 450 mg levodopa total for the remaining 4 weeks. Placebo group participants follow the same schedule but take sugar pills instead. This dosing strategy helps evaluate how different amounts of the drug may influence symptoms over time. During the trial, participants will undergo medical and psychiatric assessments, lab tests, motivation and motor function tasks, and MRI scans at various points. Researchers will measure changes in depression severity using the Hamilton Depression Rating Scale and track brain activity related to motivation and pleasure. The total participation lasts about 10 to 12 weeks, including screening and follow-up, to monitor safety and treatment effects thoroughly.

Dopaminergic Therapy for Anhedonia - 2